BSTG News and Press, Biostage From 06/13/23

Biostage to Host Investor Call PR Newswire HOLLISTON, Mass. , June 13, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to tr...

HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trau...

HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer and FDA approval to commence a clinical trial of the Biostage Esophageal Im...

HOLLISTON, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer and FDA approval to commence a clinical trial of the Biostage Esophageal Im...

Biostage Announces Chairman and CEO Transition PR Newswire Existing Board member Jerry He to replace David Green as Chairman and Chief Executive Officer; David Green to remain on the Board and support transition HOLLISTON, Mass. , March 1, 2023 ...

Regenerative medicine developer Biostage ( OTC:BSTG ) has scrapped plans for an uplisting and accompanying public offering. Biostage said in an SEC filing that it was withdrawing its S-1 application. The company had originally filed for the offering in June 2022. It later indicated in a...

Biostage Amends CEO Employment Agreement PR Newswire Biostage removes Interim qualification from Mr. Green's title, making him Chief Executive Officer. HOLLISTON, Mass. , Jan. 12, 2023 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or ...

Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer PR Newswire IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, M...

New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant PR Newswire Biostage expects to initiate patient recruitment in its first clinical trial in early 2023 HOLLISTON, Mass. , Dec. 23, 2022 /PRNewswire/ -- Biostage...

Biostage, Inc. (BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer Conference Call Participants Presentation Operator Gr...